ImageneBio, Inc. Common Stock (IMA) is a publicly traded Healthcare sector company. As of July 7, 2026, IMA trades at $5.78 with a market cap of $65.76M and a P/E ratio of 0.00. IMA moved +0.00% today. Year to date, IMA is -15.61%; over the trailing twelve months it is flat. Its 52-week range spans $3.94 to $18.00. Analyst consensus is buy with an average price target of $13.00. Rallies surfaces IMA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
ImageneBio Appoints Matt Robbins as General Counsel with 15 Years Experience: ImageneBio named Matt Robbins as General Counsel effective July 7, bringing over 15 years of corporate, securities and transactional experience at Bright Peak Therapeutics. He will oversee legal, intellectual property and compliance as the company advances Phase 2 IMG-007 trials in atopic dermatitis and alopecia areata.
| Metric | Value |
|---|---|
| Price | $5.78 |
| Market Cap | $65.76M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $18.00 |
| 52-Week Low | $3.94 |
| Volume | 21 |
| Avg Volume | 0 |
| Revenue (TTM) | $2.32B |
| Net Income | $-255.32M |
| Gross Margin | 46.09% |
3 analysts cover IMA: 0 strong buy, 2 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $13.00.